ResearchAnalysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia, Including AML-M4 and AML-M5, Treated With Venetoclax Plus Azacitidine
ResearchLong-Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax-Based Therapies
ResearchTolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia
ResearchPhase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results
ResearchVenetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study
ResearchVenetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy
ResearchRisk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model
ResearchAnalysis of CD8 Cytotoxic T-Cells in Patients With Myelodysplastic Neoplasms and T-Cell Large Granulocyte Lymphocytic Leukemia